StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)

Equities researchers at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The firm has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 12 month low of $0.01 and a 12 month high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.